WO1997004077A1 - Screening methods for enzymes and enzyme kits - Google Patents
Screening methods for enzymes and enzyme kits Download PDFInfo
- Publication number
- WO1997004077A1 WO1997004077A1 PCT/US1996/011854 US9611854W WO9704077A1 WO 1997004077 A1 WO1997004077 A1 WO 1997004077A1 US 9611854 W US9611854 W US 9611854W WO 9704077 A1 WO9704077 A1 WO 9704077A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- dna
- enzyme
- library
- enzymes
- clones
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
- C12N15/1086—Preparation or screening of expression libraries, e.g. reporter assays
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
- C12N15/1079—Screening libraries by altering the phenotype or phenotypic trait of the host
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
- C12N15/1093—General methods of preparing gene libraries, not provided for in other subgroups
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/52—Genes encoding for enzymes or proenzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
Definitions
- This invention relates to the field of preparing and screening libraries of clones containing microbially derived DNA and to protein, e.g. enzyme libraries and kits produced therefrom. More particularly, the present invention is directed to recombinant enzyme expression libraries, recombinant enzyme libraries and kits prepared therefrom which recombinant enzymes are generated from DNA obtained from microorganisms.
- a novel approach for obtaining enzymes for further use for example, for packaging into kits for further research.
- recombinant enzymes are generated from microorganisms and are classified by various enzyme characteristics.
- the enzymes can be provided as packaged enzyme screening kits, with enzymes in the kit being grouped to have selected enzyme characteristics.
- a recombinant expression library which is comprised of a multiplicity of clones which are capable of expressing recombinant enzymes.
- the expression library is produced by recovering DNA from a microorganism, cloning such DNA into an appropriate expression vector which is then used to transfect or transform an appropriate host for expression of a recombinant protein.
- genomic DNA may be recovered from either a culturable or non-culturable organism and employed to produce an appropriate recombinant expression library for subsequent determination of enzyme activity.
- such recombinant expression library may be prepared without prescreening the organism from which the library is prepared for enzyme activity. Having prepared a multiplicity of recombinant expression clones from DNA isolated from an organism, the polypeptides expressed by such clones are screened for enzyme activity and specified enzyme characteristics in order to identify and classify the recombinant clones which produce polypeptides having specified enzyme characteristics.
- the invention provides a process of screening clones having DNA from an uncultivated microorganism for a specified protein, e.g. enzyme, activity which process comprises:
- the library is produced from DNA which is recovered without culturing of an organism, particularly where the DNA is recovered from an environmental sample containing microorganisms which are not or cannot be cultured.
- DNA is ligated into a vector, particularly wherein the vector further comprises expression regulatory sequences which can control and regulate the production of a detectable enzyme activity from the ligated DNA.
- the f-factor (or fertility factor) in E. coli is a plasmid which effects high frequency transfer of itself during conjugation and less frequent transfer of the bacterial chromosome itself.
- a particularly preferred embodiment is to use a cloning vector containing an f-factor origin of replication to generate genomic libraries that can be replicated with a high degree of fidelity. When integrated with DNA from a mixed uncultured environmental sample, this makes it possible to achieve large genomic fragments in the form of a stable "environmental DNA library. "
- double stranded DNA obtained from the uncultivated DNA population is selected by:
- converting the double stranded genomic DNA into single stranded DNA recovering from the converted single stranded DNA single stranded DNA which specifically binds, such as by hybridization, to a probe DNA sequence: and convening recovered single stranded DNA to double stranded DNA.
- the probe may be directly or indirectly bound to a solid phase by which it is separated from single stranded DNA which is not hybridized or otherwise specifically bound to the probe.
- the process can also include releasing single stranded DNA from said probe after recovering said hybridized or otherwise bound single stranded DNA and amplifying the single stranded DNA so released prior to convening it to double stranded DNA.
- the invention also provides a process of screening clones having DNA from an uncultivated microorganisms for a specified protein, e.g. enzyme, activity which comprises screening for a specified gene cluster protein product activity in the library of clones prepared by: (i) recovering DNA from a DNA population derived from at least one uncultivated microorganism; and (ii) transforming a host with recovered DNA to produce a library of clones with the screens for the specified protein, e.g. enzyme, activity.
- the library is produced from gene cluster DNA which is recovered without culturing of an organism, particularly where the DNA gene clusters are recovered from an environmental sample containing microorganisms which are not or cannot be cultured.
- double-stranded gene cluster DNA obtained from the uncultivated DNA population is selected by converting the double-stranded genomic gene cluster DNA into single-stranded DNA; recovering from the converted single- stranded gene cluster polycistron DNA, single-stranded DNA which specifically binds, such as by hybridization, to a polynucleotide probe sequence; and converting recovered single-stranded gene cluster DNA to double-stranded DNA.
- Figure 1 shows an overview of the procedures used to construct an environmental library from a mixed picoplankton sample as described in Example 3.
- Figure 2 is a schematic representation of one embodiment of various tiers of chemical characteristics of an enzyme which may be employed in the present invention as described in Example 4.
- Figure 3 is a schematic representation of another embodiment of various tiers of chemical characteristics of an enzyme which may be employed in the present invention as described in Example 4.
- Figure 4 is a schematic representation of a further embodiment of various tiers of chemical characteristics of an enzyme which may be employed in the present invention as described in Example 4.
- Figure 5 is a schematic representation of a still further embodiment of various tiers of chemical characteristics of an enzyme which may be employed in the present invention as described in Example 4.
- Figure 6 shows the pH optima results produced by enzyme ESL-001-01 in the experiments described in Example 5.
- Figure 7 shows the temperature optima results produced by enzyme ESL-001- 01 in the experiments described in Example 5.
- Figure 8 shows the organic solvent tolerance results produced by enzyme ESL-001-01 in the experiments described in Example 5.
- recombinant enzymes are characterized by both physical and chemical characteristics and such chemical characteristics are preferably classified in a tiered manner such that recombinant enzymes having a chemical characteristic in common are then classified by other chemical characteristics which may or may not be more selective or specific chemical characteristic and so on, as hereinafter indicated in more detail.
- the recombinant enzymes are also preferably classified by physical characteristics and one or more tiers of the enzymes which are classified by chemical characteristics may also be classified by physical
- the term "chemical characteristic" of a recombinant enzyme refers to the substrate or chemical functionality upon which the enzyme acts and/or the catalytic reaction performed by the enzyme; e.g., the catalytic reaction may be hydrolysis (hydrolases) and the chemical functionality may be the type of bond upon which the enzyme acts (esterases cleave ester bonds) or may be the particular type of structure upon which the enzyme acts (a glycosidase which acts on glycosidic bonds).
- a recombinant enzyme which acts on glycosidic bonds may, for example, be chemically classified in accordance with the tiered system as: Tier 1 : hydrolase; Tier 2: acetal bonds; Tier 3: glycosidase.
- a "physical characteristic" with respect to a recombinant enzyme means a property (other than a chemical reaction) such as pH; temperature stability; optimum temperature for catalytic reaction; organic solvent tolerance; metal ion selectivity; detergent sensitivity, etc.
- a recombinant enzyme which is a protease in this illustration Tier 1 is hydrolase; Tier 2 is amide (peptide bond) that may be further classified in Tier 3 as to the ultimate site in the amino acid sequence where cleavage occurs; e.g., anion, cation, large hydrophobic. small hydrophobic.
- Tier 1 is hydrolase
- Tier 2 is amide (peptide bond)
- Tier 3 as to the ultimate site in the amino acid sequence where cleavage occurs; e.g., anion, cation, large hydrophobic. small hydrophobic.
- Each of the recombinant enzymes which has been classified by the side chain in Tier 3 may also be further classified by physical characteristics of the type hereinabove indicated.
- enzymes which have a specified chemical characteristic in common, e.g. , all endopeptidases (which act on internal peptide bonds) and which have a specified physical characteristic in common, e.g., all act optimally at a pH within a specified range.
- a recombinant enzyme library prepared from a microorganism is preferably classified by chemical characteristics in a tiered approach. This may be accomplished by initially testing the recombinant polypeptides generated by the library in a low selectivity screen, e.g., the catalytic reaction performed by the enzyme. This may be conveniently accomplished by screening for one or more of the six IUB classes; Oxidoreductases; transferases; hydrolases; lyases, isomerases, ligases.
- the recombinant enzymes which are determined to be positive for one or more of the IUB classes may then be rescreened for a more specific enzyme activity.
- those recombinant enzymes which have been classified as acting on ester bonds may be rescreened to determine the ability thereof to generate optically active compounds, i.e., the ability to act on specified substrates, such as meso alcohols, meso diacids, chiral alcohols, chiral acids, etc.
- the recombinant enzymes which have been classified as acting on acetals may be rescreened to classify such recombinant enzymes by a specific type of substrate upon which they act, e.g., (a) P1 sugar such as glucose, galactose, etc., (b) glucose polymer (exo-, endo- or both), etc.
- a specific type of substrate upon which they act e.g., (a) P1 sugar such as glucose, galactose, etc., (b) glucose polymer (exo-, endo- or both), etc.
- TIER 1 Divisions are based upon the catalytic reaction performed by the enzyme, e.g., hydrolysis, reduction, oxidation, etc.
- the six IUB classes will be used:
- Oxidoreductase Transferases, Hydrolases, Lyases, Isomerases, Ligases.
- TIER 2 Divisions are based upon the chemical functionality undergoing reaction, e.g., esters, amides, phosphate diesters, sulfate mono esters, aldehydes, ketones, alcohols, acetals, ketals. alkanes, olefins, aromatic rings, heteroaromatic rings, molecular oxygen, enols, etc.
- TIER 3 Divisions and subdivisions are based upon the differences between individual substrate structures which are covalently attached to the functionality undergoing reaction as defined in Tier 2. For example acetal hydrolysis: is the acetal part of glucose or galactose; or is the acetal the ⁇ or ⁇ anomer? These are the types of distinctions made in TIER 3. The divisions based upon substrate specificity are unique to each particular enzyme reaction; there will be different substrate distinctions depending upon whether the enzyme is, for example, a protease or phosphatase.
- TIER 4 Divisions are based on which of the two possible enantiomeric products the enzyme produces. This is a measure of the ability of the enzyme to selectively react with one of the two enantiomers (kinetic resolution), or the ability of the enzyme to react with a meso difunctional compound to selectively generate one of the two enantiomeric reaction products.
- the fifth tier is orthogonal to the other tiers. It is based on the physical properties of the enzymes, rather than the chemical reactions, per se:
- the fifth Tier forms a second dimension with which to classify the enzymes.
- the Fifth Tier can be applied to any of the other Tiers, but will most often be applied to the Third Tier.
- an expression library is randomly produced from the DNA of a microorganism, in particular, the genomic DNA or cDNA of the microorganism and the recombinant proteins or polypeptides produced by such expression library are screened to classify the recombinant enzymes by different enzyme characteristics.
- the recombinant proteins are screened for one or more particular chemical characteristics and the enzymes identified as having such characteristics are then rescreened for a more specific chemical characteristic and this rescreening may be repeated one or more times.
- the recombinant enzymes are also screened to classify such enzymes by one or more physical characteristics. In this manner, the recombinant enzymes generated from the DNA of a microorganism are classified by both chemical and physical
- the tiered approach of the present invention is not limited to a tiered approach in which, for example, the tiers are more restrictive.
- the tiered approach is also applicable to using a tiered approach in which, for example, the first tier is "wood degrading" enzymes.
- the second chemical tier could then, for example, be the type of enzyme which is a "wood degrading" enzyme.
- the first tier or any other tier could be physical characteristics and the next tier could be specified chemical characteristics.
- the present invention is generally applicable to providing recombinant enzymes and recombinant enzyme libraries wherein various enzymes are classified by different chemical and/or physical characteristics.
- the microorganisms from which the recombinant libraries may be prepared include prokaryotic microorganisms, such as Eubacteria and Archaebacteria, and lower eukaryotic microorganisms such as fungi, some algae and protozoa.
- the microorganisms may be cultured microorganisms or uncultured microorganisms obtained from environmental samples and such microorganisms may be
- extremophiles such as thermophiles. hyperthermophiles, psychrophiles.
- the library is produced from DNA which is recovered without culturing of an organism, particularly where the DNA is recovered from an environmental sample containing microorganisms which are not or cannot be cultured.
- Sources of microorganism DNA as a starting material library from which DNA is obtained are particularly contemplated to include environmental samples, such as microbial samples obtained from Arctic and Antarctic ice, water or permafrost sources, materials of volcanic origin, materials from soil or plant sources in tropical areas, etc.
- genomic DNA may be recovered from either uncultured or non-culturable organism and employed to produce an appropriate library of clones for subsequent determination of enzyme activity.
- genes Bacteria and many eukaryotes have a coordinated mechanism for regulating genes whose products are involved in related processes.
- the genes are clustered, in structures referred to as "gene clusters, " on a single chromosome and are transcribed together under the control of a single regulatory sequence, including a single promoter which initiates transcription of the entire cluster.
- the gene cluster, the promoter, and additional sequences that function in regulation altogether are referred to as an "operon" and can include up to 20 or more genes, usually from 2 to 6 genes.
- a gene cluster is a group of adjacent genes that are either identical or related, usually as to their function.
- Some gene families consist of identical members. Clustering is a prerequisite for maintaining identity between genes, although clustered genes are not necessarily identical. Gene clusters range from extremes where a duplication is generated to adjacent related genes to cases where hundreds of identical genes lie in a tandem array. Sometimes no significance is discernable in a repetition of a particular gene. A principal example of this is the expressed duplicate insulin genes in some species, whereas a single insulin gene is adequate in other mammalian species.
- gene clusters undergo continual reorganization and, thus, the ability to create heterogeneous libraries of gene clusters from, for example, bacterial or other prokaryote sources is valuable in determining sources of novel proteins, particularly including proteins, e.g. enzymes, such as. for example, the polyketide synthases that are responsible for the synthesis of polyketides having a vast array of useful activities.
- proteins e.g. enzymes, such as. for example, the polyketide synthases that are responsible for the synthesis of polyketides having a vast array of useful activities.
- Other types of proteins that are the product(s) of gene clusters are also contemplated, including, for example, antibiotics, antivirals. antitumor agents and regulatory proteins, such as insulin.
- Polyketides are molcules which are an extremely rich source of bioactivities, including antibiotics (such as tetracyclines and erythromycin), anti-cancer agents (daunomycin). immunosuppressants (FK506 and rapamycin), and veterinary products (monensin). Many polyketides (produced by polyketide synthases) are valuable as therapeutic agents. Polyketide synthases are multifunctional enzymes that catalyze the biosynthesis of a huge variety of carbon chains differing in length and patterns of functionality and cyclization. Polyketide synthase genes fall into gene clusters and at least one type (designated type I) of polyketide synthases have large size genes and enzymes, complicating genetic manipulation and in vitro studies of these
- derived or “isolated” means that material is removed from its original environment (e.g. , the natural environment if it is naturally occurring).
- a naturally-occurring polynucleotide or polypeptide present in a living animal is not isolated, but the same polynucleotide or polypeptide separated from some or all of the coexisting materials in the natural system, is isolated.
- the expression library may be produced from environmental samples in which case DNA may be recovered without culturing of an organism or the DNA may be recovered from a cultured organism.
- the sized DNA is cloned into an appropriate expression vector and
- the expression vector which is used is preferably one which includes a promoter which is known to function in the selected host in case the native genomic promoter does not function in the host.
- phage As representative examples of expression vectors which may be used for preparing an expression library, there may be mentioned phage, plasmids. phagemids cosmids, phosmids, bacterial artificial chromosomes, P1-based artificial
- the vector may also include a tag of a type known in the art to facilitate purification.
- CTAB DNA Isolation
- Ligate to lambda vector Ligate to lambda vector (Lambda ZAP II and gt11)
- Blunt DNA (Mung Bean Nuclease) Ligate to adaptor containing a Not I site and conjugated to magnetic beads
- Ligate to lambda vector Ligate to lambda vector (Lambda ZAP II and gt1 1)
- the probe D ⁇ A used for selectively recovering D ⁇ A of interest from the D ⁇ A derived from the at least one uncultured microorganism can be a full-length coding region sequence or a partial coding region sequence of D ⁇ A for an enzyme of known activity, a phylogenetic marker or other identified D ⁇ A sequence.
- the original D ⁇ A library can be preferably probed using mixtures of probes comprising at least a portion of the D ⁇ A sequence encoding the specified activity.
- These probes or probe libraries are preferably single-stranded and the microbial D ⁇ A which is probed has preferably been converted into single-stranded form.
- the probes that are particularly suitable are those derived from D ⁇ A encoding enzymes having an activity similar or identical to the specified enzyme activity which is to be screened.
- Hybridization techniques for probing a microbial D ⁇ A library to isolate D ⁇ A of potential interest are well known in the art and any of those which are described in the literature are suitable for use herein, particularly those which use a solid phase-bound, directly or indirectly bound, probe DNA for ease in separation from the remainder of the DNA derived from the microorganisms.
- the probe DNA is "labeled" with one partner of a specific binding pair (i.e. a ligand) and the other partner of the pair is bound to a solid matrix to provide ease of separation of target from its source.
- the ligand and specific binding partner can be selected from, in either orientation, the following: (1) an antigen or hapten and an antibody or specific binding fragment thereof; (2) biotin or iminobiotin and avidin or streptavidin; (3) a sugar and a lectin specific therefor; (4) an enzyme and an inhibitor therefor; (5) an apoenzyme and cofactor: (6) complementary homopolymeric oligonucleotides; and (7) a hormone and a receptor therefor.
- the solid phase is preferably selected from: ( 1 ) a glass or polymeric surface; (2) a packed column of polymeric beads; and (3) magnetic or paramagnetic particles.
- the library of clones prepared as described above can be screened directly for a desired, e.g. enzymatic, activity without the need for culture expansion, amplification or other supplementary procedures. However, in one preferred embodiment, it is considered desirable to amplify the DNA recovered from the individual clones such as by PCR.
- the selectively isolated DNA is separated from the probe DNA after isolation. It is then amplified before being used to transform hosts.
- the double stranded DNA selected to include as at least a portion thereof a predetermined DNA sequence can be rendered single stranded, subjected to amplification and reannealed to provide amplified numbers of selected double stranded DNA. Numerous amplification methodologies are now well known in the art.
- the selected DNA is then used for preparing a library for screening by transforming a suitable organism. Hosts, particularly those specifically identified herein as preferred, are transformed by artificial introduction of the vectors containing the target DNA by inoculation under conditions conducive for such transformation.
- expression vectors which may be used there may be mentioned viral panicles, baculovirus, phage, plasmids. phagemids, cosmids, phosmids. bacterial artificial chromosomes, viral DNA (e.g. vaccinia, adenovirus, foul pox virus, pseudorabies and derivatives of SV40), P1-based artificial
- the DNA may be included in any one of a variety of expression vectors for expressing a polypeptide.
- Such vectors include chromosomal, nonchromosomal and synthetic DNA sequences. Large numbers of suitable vectors are known to those of skill in the art. and are commercially available.
- Bacterial pQE70, pQE60, pQE-9 (Qiagen), psiX174, pBluescript SK, pBluescript KS, pNH8A, pNH16a, pNH18A, pNH46A (Stratagene); pTRC99a, pKK223-3, pKK233-3, pDR540, pRIT5 (Pharmacia); Eukaryotic:
- pWLNEO pSV2CAT
- pOG44 pXT1
- pSG Stratagene
- pSVK3 pSVK3
- pBPV pMSG
- pSVL pSVL
- any other plasmid or vector may be used as long as they are replicable and viable in the host.
- a particularly preferred type of vector for use in the present invention contains an f-factor origin of replication.
- the f-factor (or fertility factor) in E. coli is a plasmid which effects high frequency transfer of itself during conjugation and less frequent transfer of the bacterial chromosome itself.
- a particularly preferred embodiment is to use cloning vectors, referred to as "fosmids” or bacterial artificial chromosome (BAC) vectors. These are derived from the E. coli f-factor and are able to stably integrate large segments of genomic DNA. When integrated with DNA from a mixed uncultured environmental sample, this makes it possible to achieve large genomic fragments in the form of a stable "environmental DNA library. "fosmids" or bacterial artificial chromosome (BAC) vectors.
- the DNA derived from a microorganism(s) may be inserted into the vector by a variety of procedures.
- the DNA sequence is inserted into an appropriate restriction endonuclease site(s) by procedures known in the art. Such procedures and others are deemed to be within the scope of those skilled in the art.
- the DNA sequence in the expression vector is operatively linked to an appropriate expression control sequence(s) (promoter) to direct mRNA synthesis.
- promoter particularly named bacterial promoters include lad, lacZ, T3, T7, gpt, lambda P R , P L and trp.
- Eukaryotic promoters include CMV immediate early. HSV thymidine kinase, early and late SV40. LTRs from retrovirus, and mouse metallofhionein-I. Selection of the appropriate vector and promoter is well within the level of ordinary skill in the art.
- the expression vector also contains a ribosome binding site for translation initiation and a transcription terminator.
- the vector may also include appropriate sequences for amplifying expression. Promoter regions can be selected from any desired gene using CAT (chloramphenicol transferase) vectors or other vectors with selectable markers.
- the expression vectors preferably contain one or more selectable marker genes to provide a phenotypic trait for selection of transformed host cells such as dihydrofolate reductase or neomycin resistance for eukaryotic cell culture. or such as tetracycline or ampicillin resistance in E. coli.
- recombinant expression vectors will include origins of replication and selectable markers permitting transformation of the host cell, e.g. , the ampicillin resistance gene of E. coli and S. cerevisiae TRP1 gene, and a promoter derived from a highly-expressed gene to direct transcription of a downstream structural sequence.
- promoters can be derived from operons encoding glycolytic enzymes such as 3- phosphogly cerate kinase (PGK), ⁇ -factor, acid phosphatase, or heat shock proteins, among others.
- the heterologous structural sequence is assembled in appropriate phase with translation initiation and termination sequences, and preferably, a leader sequence capable of directing secretion of translated protein into the periplasmic space or extracellular medium.
- the DNA selected and isolated as hereinabove described is introduced into a suitable host to prepare a library which is screened for the desired enzyme activity.
- the selected DNA is preferably already in a vector which includes appropriate control sequences whereby selected DNA which encodes for an enzyme may be expressed, for detection of the desired activity.
- the host cell can be a higher eukaryotic cell, such as a mammalian cell, or a lower eukaryotic cell, such as a yeast cell, or the host cell can be a prokaryotic cell, such as a bacterial cell.
- Introduction of the construct into the host cell can be effected by transformation, calcium phosphate transfection, DEAE-Dextran mediated transfection, DMSO or
- bacterial cells such as E. coli. Bacillus, Streptomyces . Salmonella typhimurium; fungal cells, such as yeast; insect cells such as Drosophila S2 and Spodoptera 5/9; animal cells such as CHO. COS or Bowes melanoma: adenoviruses; plant cells, etc.
- bacterial cells such as E. coli. Bacillus, Streptomyces . Salmonella typhimurium
- fungal cells such as yeast
- insect cells such as Drosophila S2 and Spodoptera 5/9
- animal cells such as CHO.
- COS or Bowes melanoma adenoviruses; plant cells, etc.
- the selection of an appropriate host is deemed to be within the scope of those skilled in the art from the teachings herein.
- Host cells are genetically engineered (transduced or transformed or
- the engineered host cells can be cultured in
- the recombinant enzymes in the library which are classified as described herein may or may not be sequenced and may or may not be in a purified form.
- the screening for chemical characteristics may be effected on individual expression clones or may be initially effected on a mixture of expression clones to ascertain whether or not the mixture has one or more specified enzyme activities. If the mixture has a specified enzyme activity, then the individual clones may be rescreened for such enzyme activity or for a more specific activity. Thus, for example, if a clone mixture has hydrolase activity, then the individual clones may be recovered and screened to determine which of such clones has hydrolase activity.
- a reagent package or kit is prepared by placing in the kit or package, e.g. , in suitable containers, at least three different recombinant enzymes with each of the at least three different recombinant enzymes having at least two enzyme characteristics in common.
- one common characteristic is a chemical characteristic or property and the other common characteristic is a physical characteristic or property; however, it is possible to prepare kits which have two or more chemical characteristics or properties in common and no physical characteristics or property in common and vice versa.
- a variety of enzyme kits or packages can be prepared having a variety of selected chemical and/or physical characteristics which can be formulated to contain three or more recombinant enzymes in which at least three and preferably all of the recombinant enzymes have in common at least one chemical characteristic and have in common at least one physical characteristic.
- the kit should contain an appropriate label specifying such common characteristics.
- kits have in common the most specific chemical characteristic specified on the label.
- label is used in its broadest sense and includes package inserts or literature associated or distributed in conjunction with the kit or package. Thus, for example, if the kit is labeled for a specific substrate (one of the Tier 3 examples above), then for example, at least three of the enzymes in the kit would act on such substrate.
- kits will preferably contain more than three enzymes, for example, five, six or more enzymes and in a preferred embodiment at least three and preferably a majority and in some cases all of the recombinant enzymes in the kit will have at least two enzyme properties or characteristics in common, as hereinabove described.
- the recombinant enzymes in the kits may have two or more enzymes in a single container or individual enzymes in individual containers or various
- the library may be screened for a specified enzyme activity by procedures known in the art.
- the enzyme activity may be screened for one or more of the six IUB classes; oxidoreductases, transferases, hydrolases, lyases, isomerases and ligases.
- the recombinant enzymes which are determined to be positive for one or more of the IUB classes may then be rescreened for a more specific enzyme activity.
- the library may be screened for a more specialized enzyme activity.
- the library may be screened for a more specialized enzyme activity.
- the library may be screened for a more specialized activity, i.e. the type of bond on which the hydrolase acts.
- the library may be screened to ascertain those hydrolases which act on one or more specified chemical
- the clones which are identified as having the specified enzyme activity may then be sequenced to identify the DNA sequence encoding an enzyme having the specified activity.
- the DNA sequence encoding an enzyme having the specified activity may then be sequenced to identify the DNA sequence encoding an enzyme having the specified activity.
- the screening for enzyme activity may be effected on individual expression clones or may be initially effected on a mixture of expression clones to ascertain whether or not the mixture has one or more specified enzyme activities. If the mixture has a specified enzyme activity, then the individual clones may be rescreened for such enzyme activity or for a more specific activity. Thus, for example, if a clone mixture has hydrolase activity, then the individual clones may be recovered and screened to determine which of such clones has hydrolase activity.
- the expression libraries may be screened for one or more selected chemical characteristics. Selected representative chemical characteristics are described below but such characteristics do not limit the present invention. Moreover, the expression libraries may be screened for some or all of the characteristics. Thus, some of the chemical characteristics specified herein may be determined in all of the libraries, none of the libraries or in only some of the libraries.
- the recombinant enzymes may also be tested and classified by physical properties. For example, the recombinant enzymes may be classified by physical properties such as follows:
- the recombinant enzymes of the libraries and kits of the present invention may be used for a variety of purposes and the present invention by providing a plurality of recombinant enzymes classified by a plurality of different enzyme characteristics permits rapid screening of enzymes for a variety of applications.
- the present invention permits assembly of enzyme kits which contain a plurality of enzymes which are capable of operating on a specific bond or a specific substrate at specified conditions to thereby enable screening of enzymes for a variety of applications.
- Thermococcus GU5L5 cell pellet was lysed and the DNA isolated by literature procedures (Current Protocols in Molecular Biology, 2.4.1, 1987). Approximately 100 ⁇ g of the isolated DNA was resuspended in TE buffer and vigorously passed through a 25 gauge double-hubbed needle until the sheared fragments were in the size range of 0.5-10.0 Kb (3.0 Kb average). The DNA ends were "polished” or blunted with Mung Bean Nuclease (300 units, 37°C, 15 minutes), and EcoRI restriction sites in the target DNA protected with EcoRI Methylase (200 units, 37°C, 1 hour). EcoRI linkers [GGAATTCC] were ligated to the
- the linkers were cut back with EcoRI restriction endonuclease (200 units, 37°C, 1.5 hours) and the DNA size fractionated by sucrose gradient (Maniatis, T., Fritsch, E.F. , and Sambrook, J. , Molecular Cloning, Cold Spring Harbor Press, New York, 1982).
- the prepared target DNA was ligated to the Lambda ZAP ® II vector (Stratagene), packaged using in vitro lambda packaging extracts and grown on XL1-Blue MRF' E. coli strain according to the manufacturer.
- the pBluescript ® phagemids were excised from the lambda library, and grown in E.
- Figure 1 shows an overview of the procedures used to construct an environmental library from a mixed picoplankton sample. The goal was to construct a stable, large insert DNA library representing picoplankton genomic DNA.
- the cell suspension was mixed with one volume of 1 % molten Seaplaque LMP agarose (FMC) cooled to 40 °C, and then immediately drawn into a 1 ml syringe.
- the syringe was sealed with parafilm and placed on ice for 10 min.
- the cell-containing agarose plug was extruded into 10 ml of Lysis Buffer (10mM Tris pH 8.0, 50 mM NaCl, 0.1M EDTA, 1 % Sarkosyl, 0.2% sodium deoxycholate, a mg/ml lysozyme) and incubated at 37°C for one hour.
- Lysis Buffer 10mM Tris pH 8.0, 50 mM NaCl, 0.1M EDTA, 1 % Sarkosyl, 0.2% sodium deoxycholate, a mg/ml lysozyme
- the agarose plug was then transferred to 40 mis of ESP Buffer (1 % Sarkosyl, 1 mg/ml proteinase-K, in 0.5M EDTA), and incubated at 55°C for 16 hours. The solution was decanted and replaced with fresh ESP Buffer, and incubated at 55 °C for an additional hour. The agarose plugs were then placed in 50 mM EDTA and stored at 4°C shipboard for the duration of the oceanographic cruise.
- ESP Buffer 1 % Sarkosyl, 1 mg/ml proteinase-K, in 0.5M EDTA
- the solution was then changed to 250 ⁇ l of the same buffer containing 4U of Sau3A1 (NEB), equilibrated to 37°C in a water bath, and then incubated on a rocking platform in a 37°C incubator for 45 min.
- the plug was transferred to a 1.5 ml microcentrifuge tube and incubated at 68°C for 30 min to inactivate the protein, e.g. enzyme, and to melt the agarose.
- the agarose was digested and the DNA dephosphorylased using Gelase and HK-phosphatase
- Agarose plugs prepared from this picoplankton sample were chosen for subsequent fosmid library preparation.
- Each 1 ml agarose plug from this site contained approximately 7.5 ⁇ 10 5 cells, therefore approximately 5.4 ⁇ 10 5 cells were present in the 72 ⁇ l slice used in the preparation of the partially digested DNA.
- Vector arms were prepared from pFOSl as described (Kim et al. , Stable propagation of casmid sized human DNA inserts in an F factor based vector. Nucl. Acids Res., 20: 10832- 10835, 1992). Briefly, the plasmid was completely digested with AstII. dephosphorylated with HK phosphatase, and then digested with BamHI to generate two arms, each of which contained a cos site in the proper orientation for cloning and packaging ligated DNA between 35-45 kbp.
- the partially digested picoplankton DNA was ligated overnight to the PFOS1 arms in a 15 ⁇ l ligation reaction containing 25 ng each of vector and insert and 1 U of T4 DNA ligase (Boehringer-Mannheim).
- the ligated DNA in four microliters of this reaction was in vitro packaged using the Gigapack XL packaging system (Stratagene).
- the fosmid particles transfected to E. coli strain DH10B (BRL), and the cells spread onto LB cm15 plates.
- the resultant fosmid clones were picked into 96-well microliter dishes containing LB cm15 supplemented with 7% glycerol. Recombinant fosmids, each containing ca.
- Tier 4 The two possible enantiomeric products which the enzyme may produce from a substrate.
- the eleven plates of the Source Library were used to multiply inoculate a single plate (the "Condensed Plate") containing in each well 200 ⁇ L of LB
- the two condensed daughter plates were incubated at 37 °C also for 18 h.
- the condensed daughter plates were then heated at 70°C for 45 min. to kill the cells and inactivate the host E.coli enzymes.
- a stock solution of 5mg/mL morphourea phenylalanyl-7-amino-4-trifluoromethyl coumarin (MuPheAFC, the 'substrate') in DMSO was diluted to 600 ⁇ M with 50 mM pH 7.5 Hepes buffer containing 0.6 mg/mL of the detergent dodecyl maltoside.
- the umbelliferone and rhodamine were added as 600 ⁇ M stock solutions in 50 ⁇ L of Hepes buffer.
- arginine rhodamine derivative was also turned over by this activity, but the lipase substrate, methyl umbelliferone heptanoate, and protein, fluorescein-conjugated casein, did not function as substrates.
- the Tier 1 classification is 'hydrolase' and the Tier 2 classification is amide bond. There is no cross reactivity with the Tier 2-ester classification.
- a recombinant clone from the library which has been characterized in Tier 1 as hydrolase and in Tier 2 as amide may then be tested in Tier 3 for various specificities.
- the various classes of Tier 3 are followed by a parenthetical code which identifies the substrates of Table 1 which are used in identifying such specificities of Tier 3.
- a recombinant clone from the library which has been characterized in Tier 1 as hydrolase and in Tier 2 as ester may then be tested in Tier 3 for various specificities.
- the various classes of Tier 3 are followed by a parenthetical code which identifies the substrates of Tables 2 and 2 which are used in identifying such specificities of Tier 3.
- R 2 represents the alcohol portion of the ester and R 1 represents the acid portion of the ester.
- a recombinant clone from the library which has been characterized in Tier 1 as hydrolase and in Tier 2 as acetal may then be tested in Tier 3 for various specificities.
- the various classes of Tier 3 are followed by a parenthetical code which identifies the substrates of Table 4 which are used in identifying such specificities of Tier 3.
- Enzymes may be classified in Tier 4 for the chirality of the product(s) produced by the enzyme.
- chiral amino esters may be determined using at least the following substrates:
- enantiomeric excess is determined by either chiral high performance liquid chromatography (HPLC) or chiral capillary electrophoresis (CE). Assays are performed as follows: two hundred ⁇ L of the appropriate buffer is added to each well of a 96-well white microtiter plate, followed by 50 ⁇ L of partially or completely purified enzyme solution; 50 ⁇ L of substrate is added and the increase in
- Enantioselectivity was determined for one of the esterases identified as follows. For the reaction to form (transesterification) or breakdown (hydrolysis) ⁇ -methyl benzyl acetate, the enantioselectivity of the enzyme was obtained by determining: ee c (the enantiomeric excess (ee) of the unreacted substrate). ee P (the ee of the hydrolyzed product), and c (the percent conversion of the reaction). The enantiomeric excess was by determined chiral high performance gas chromatography (GC). Chromatography conditions were as follows:
- Sample Preparation Samples were filtered through a 0.2 ⁇ m, 13 mm diameter PTFE filter.
- Oven 90°C for 1 min, then 90°C to 150°C at 5°C/min.
- Carrier Gas Helium, 1 mL/min for 2 min then 1 mL/min. to 3 mL/min at 0.2 mL/min.
- the transesterification reaction was performed according to the procedure described in: Organic solvent tolerance. Water immiscible solvents. See below.
- Transesterification with Enzyme ESL-001-01 gave the following results:
- the hydrolysis reaction was performed as follows: Fifty ⁇ L of a 10 mM solution of ⁇ -methyl benzyl acetate in 10% aqueous DMSO (v/v) was added to 200 ⁇ L of 100 mM, pH 6.9 phosphate buffer. To this solution was added 250 ⁇ L of Enzyme ESL-001-01 (2 mg/mL in 100 mM, pH 6.9 phosphate buffer) and the reaction heated at 70°C for 15 min. The reaction was worked up according to the following procedure: remove 250 ⁇ L of hydrolysis reaction mixture and add to a 1 mL Eppendorf tube.
- This example describes procedures for testing for certain physical
- Enzyme ESL-001-01 (1 :4000 dilution of a 1 mg/mL stock solution in Hepes buffer) were incubated at 70, 80, and 90°C. At selected time points 25 ⁇ L aliquots were removed and assayed as above in a 96 well microtiter plate with 200 ⁇ L of 100 ⁇ M 4-methylumbelliferyl palmitate and 0.6 mg/mL dodecyl maltoside. This data was used to determine the half life for inactivation of the enzyme.
- the specific activity was determined using 100 ⁇ M 4-methyl umbelliferyl heptanoate at 90°C in pH 6.9 MOPS buffer.
- the specific activity obtained for Enzyme ESL-001-01 was 1662 ⁇ mol/min-mg.
- This example describes procedures for testing for substrate specificity of a recombinant clone of a library.
Abstract
Description
Claims
Priority Applications (11)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DK96925351T DK0839185T3 (en) | 1995-07-18 | 1996-07-17 | Screening methods for enzymes and enzyme test kits |
IL12291896A IL122918A0 (en) | 1995-07-18 | 1996-07-17 | Screening methods for enzymes and enzyme kits |
DE69636721T DE69636721T2 (en) | 1995-07-18 | 1996-07-17 | SCREENING PROCEDURE FOR ENZYMES AND ENZYM KITS |
AU65477/96A AU6547796A (en) | 1995-07-18 | 1996-07-17 | Screening methods for enzymes and enzyme kits |
EP96925351A EP0839185B1 (en) | 1995-07-18 | 1996-07-17 | Screening methods for enzymes and enzyme kits |
JP50682997A JP2002514894A (en) | 1995-07-18 | 1996-07-17 | Enzyme screening method and enzyme kit |
US08/983,367 US6168919B1 (en) | 1996-07-17 | 1996-07-17 | Screening methods for enzymes and enzyme kits |
CA2227342A CA2227342C (en) | 1995-07-18 | 1996-07-17 | Screening methods for enzymes and enzyme kits |
AU69582/00A AU767618C (en) | 1995-07-18 | 2000-10-26 | Screening methods for enzymes and enzyme kits |
US09/753,752 US20020058254A1 (en) | 1995-07-18 | 2001-01-02 | Screening methods for enzymes and enzyme kits |
AU2004200703A AU2004200703A1 (en) | 1995-07-18 | 2004-02-20 | Screening methods for enzymes and enzyme kits |
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/503,606 US6004788A (en) | 1995-07-18 | 1995-07-18 | Enzyme kits and libraries |
US56899495A | 1995-12-07 | 1995-12-07 | |
US08/508,994 | 1996-06-03 | ||
US08/657,409 US5958672A (en) | 1995-07-18 | 1996-06-03 | Protein activity screening of clones having DNA from uncultivated microorganisms |
US08/503,606 | 1996-06-03 | ||
US08/657,409 | 1996-06-03 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1997004077A1 true WO1997004077A1 (en) | 1997-02-06 |
Family
ID=27054566
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1996/011854 WO1997004077A1 (en) | 1995-07-18 | 1996-07-17 | Screening methods for enzymes and enzyme kits |
Country Status (10)
Country | Link |
---|---|
US (8) | US5958672A (en) |
EP (2) | EP1696025B1 (en) |
JP (1) | JP2002514894A (en) |
AT (2) | ATE465246T1 (en) |
AU (1) | AU6547796A (en) |
CA (1) | CA2227342C (en) |
DE (2) | DE69638168D1 (en) |
DK (2) | DK0839185T3 (en) |
ES (1) | ES2277346T3 (en) |
WO (1) | WO1997004077A1 (en) |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0866853A1 (en) * | 1995-12-07 | 1998-09-30 | Recombinant Biocatalysis Inc. | Method of screening for enzyme activity |
WO1999015897A1 (en) * | 1997-09-19 | 1999-04-01 | Chiron Corporation | Subtractive protein screening for gene identification |
EP1009858A1 (en) * | 1997-06-16 | 2000-06-21 | Diversa Corporation | High throughput screening for novel enzymes |
EP1025262A1 (en) * | 1997-08-26 | 2000-08-09 | Diversa Corporation | Screening for novel bioactivities |
US6242211B1 (en) | 1996-04-24 | 2001-06-05 | Terragen Discovery, Inc. | Methods for generating and screening novel metabolic pathways |
US6261842B1 (en) | 1997-10-23 | 2001-07-17 | Wisconsin Alumni Research Foundation | Microorganism genomics, compositions and methods related thereto |
WO2001081567A2 (en) * | 2000-04-26 | 2001-11-01 | Wisconsin Alumni Research Foundation | Method for producing genomic libraries and genomic libraries produced therewith |
US6495348B1 (en) | 1993-10-07 | 2002-12-17 | Regents Of The University Of Minnesota | Mitomycin biosynthetic gene cluster |
US6846627B2 (en) * | 1997-10-15 | 2005-01-25 | Diversa Corporation | Screening for novel compounds which regulate biological interactions |
WO2007136833A2 (en) * | 2006-05-19 | 2007-11-29 | Codon Devices, Inc. | Methods and compositions for aptamer production and uses thereof |
Families Citing this family (163)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5605793A (en) | 1994-02-17 | 1997-02-25 | Affymax Technologies N.V. | Methods for in vitro recombination |
US6165793A (en) * | 1996-03-25 | 2000-12-26 | Maxygen, Inc. | Methods for generating polynucleotides having desired characteristics by iterative selection and recombination |
US6995017B1 (en) | 1994-02-17 | 2006-02-07 | Maxygen, Inc. | Methods for generating polynucleotides having desired characteristics by iterative selection and recombination |
US6406855B1 (en) | 1994-02-17 | 2002-06-18 | Maxygen, Inc. | Methods and compositions for polypeptide engineering |
US6335160B1 (en) | 1995-02-17 | 2002-01-01 | Maxygen, Inc. | Methods and compositions for polypeptide engineering |
US5837458A (en) | 1994-02-17 | 1998-11-17 | Maxygen, Inc. | Methods and compositions for cellular and metabolic engineering |
US6309883B1 (en) | 1994-02-17 | 2001-10-30 | Maxygen, Inc. | Methods and compositions for cellular and metabolic engineering |
US6395547B1 (en) | 1994-02-17 | 2002-05-28 | Maxygen, Inc. | Methods for generating polynucleotides having desired characteristics by iterative selection and recombination |
US20060257890A1 (en) * | 1996-05-20 | 2006-11-16 | Maxygen, Inc. | Methods and compositions for cellular and metabolic engineering |
US6117679A (en) | 1994-02-17 | 2000-09-12 | Maxygen, Inc. | Methods for generating polynucleotides having desired characteristics by iterative selection and recombination |
US6168919B1 (en) * | 1996-07-17 | 2001-01-02 | Diversa Corporation | Screening methods for enzymes and enzyme kits |
US7018793B1 (en) * | 1995-12-07 | 2006-03-28 | Diversa Corporation | Combinatorial screening of mixed populations of organisms |
US6794127B1 (en) * | 1997-06-16 | 2004-09-21 | Diversa Corporation | Capillary array-based sample screening |
US6506602B1 (en) | 1996-03-25 | 2003-01-14 | Maxygen, Inc. | Methods for generating polynucleotides having desired characteristics by iterative selection and recombination |
US6096548A (en) | 1996-03-25 | 2000-08-01 | Maxygen, Inc. | Method for directing evolution of a virus |
US7883872B2 (en) * | 1996-10-10 | 2011-02-08 | Dyadic International (Usa), Inc. | Construction of highly efficient cellulase compositions for enzymatic hydrolysis of cellulose |
US5811381A (en) * | 1996-10-10 | 1998-09-22 | Mark A. Emalfarb | Cellulase compositions and methods of use |
US20070009930A1 (en) * | 1996-12-18 | 2007-01-11 | Maxygen, Inc. | Methods and compositions for polypeptide engineering |
US6399789B1 (en) * | 1996-12-18 | 2002-06-04 | Kosan Biosciences, Inc. | Multi-plasmid method for preparing large libraries of polyketides and non-ribosomal peptides |
US7148054B2 (en) * | 1997-01-17 | 2006-12-12 | Maxygen, Inc. | Evolution of whole cells and organisms by recursive sequence recombination |
JP4062366B2 (en) | 1997-01-17 | 2008-03-19 | マキシジェン,インコーポレイテッド | Evolution of whole cells and organisms by recursive sequence recombination |
US6326204B1 (en) | 1997-01-17 | 2001-12-04 | Maxygen, Inc. | Evolution of whole cells and organisms by recursive sequence recombination |
US6159688A (en) | 1997-03-18 | 2000-12-12 | Novo Nordisk A/S | Methods of producing polynucleotide variants |
US6159687A (en) * | 1997-03-18 | 2000-12-12 | Novo Nordisk A/S | Methods for generating recombined polynucleotides |
US6153410A (en) * | 1997-03-25 | 2000-11-28 | California Institute Of Technology | Recombination of polynucleotide sequences using random or defined primers |
US20030013115A1 (en) * | 1997-06-16 | 2003-01-16 | Diversa Corporation, A Delaware Corporation | Capillary array-based sample screening |
US20020015997A1 (en) * | 1997-06-16 | 2002-02-07 | Lafferty William Michael | Capillary array-based sample screening |
US6833242B2 (en) * | 1997-09-23 | 2004-12-21 | California Institute Of Technology | Methods for detecting and sorting polynucleotides based on size |
WO1999023107A1 (en) | 1997-10-31 | 1999-05-14 | Maxygen, Incorporated | Modification of virus tropism and host range by viral genome shuffling |
DK1036198T3 (en) | 1997-12-08 | 2013-01-02 | California Inst Of Techn | Method for Preparation of Polynucleotide and Polypeptide Sequences |
US6541011B2 (en) | 1998-02-11 | 2003-04-01 | Maxygen, Inc. | Antigen library immunization |
US7390619B1 (en) | 1998-02-11 | 2008-06-24 | Maxygen, Inc. | Optimization of immunomodulatory properties of genetic vaccines |
JP2002513550A (en) | 1998-05-01 | 2002-05-14 | マキシジェン, インコーポレイテッド | Optimization of pest resistance genes using DNA shuffling |
US6365408B1 (en) | 1998-06-19 | 2002-04-02 | Maxygen, Inc. | Methods of evolving a polynucleotides by mutagenesis and recombination |
JP2002522072A (en) | 1998-08-12 | 2002-07-23 | マキシジェン, インコーポレイテッド | DNA shuffling of monooxygenase gene for production of industrial chemicals. |
JP2002522089A (en) * | 1998-08-12 | 2002-07-23 | マキシジェン, インコーポレイテッド | DNA shuffling to produce herbicide-selective crops |
US20060242731A1 (en) * | 1998-08-12 | 2006-10-26 | Venkiteswaran Subramanian | DNA shuffling to produce herbicide selective crops |
ES2237159T3 (en) * | 1998-10-06 | 2005-07-16 | Mark Aaron Emalfarb | TRANSFORMATION SYSTEM IN THE FIELD OF FILAMENT MICOTIC FUNGI IN CHRYSOSPORIUM. |
US6500639B2 (en) | 1998-10-07 | 2002-12-31 | Maxygen, Inc. | DNA shuffling to produce nucleic acids for mycotoxin detoxification |
US6368793B1 (en) * | 1998-10-14 | 2002-04-09 | Microgenomics, Inc. | Metabolic selection methods |
AU1619400A (en) | 1998-11-10 | 2000-05-29 | Maxygen, Inc. | Modified adp-glucose pyrophosphorylase for improvement and optimization of plantphenotypes |
US6438561B1 (en) * | 1998-11-19 | 2002-08-20 | Navigation Technologies Corp. | Method and system for using real-time traffic broadcasts with navigation systems |
US20040005673A1 (en) * | 2001-06-29 | 2004-01-08 | Kevin Jarrell | System for manipulating nucleic acids |
DE60042730D1 (en) * | 1999-01-05 | 2009-09-24 | Univ Boston | IMPROVED CLONING PROCESS |
US6436675B1 (en) | 1999-09-28 | 2002-08-20 | Maxygen, Inc. | Use of codon-varied oligonucleotide synthesis for synthetic shuffling |
US20030054390A1 (en) * | 1999-01-19 | 2003-03-20 | Maxygen, Inc. | Oligonucleotide mediated nucleic acid recombination |
US6376246B1 (en) | 1999-02-05 | 2002-04-23 | Maxygen, Inc. | Oligonucleotide mediated nucleic acid recombination |
US6917882B2 (en) * | 1999-01-19 | 2005-07-12 | Maxygen, Inc. | Methods for making character strings, polynucleotides and polypeptides having desired characteristics |
WO2000042559A1 (en) * | 1999-01-18 | 2000-07-20 | Maxygen, Inc. | Methods of populating data structures for use in evolutionary simulations |
AU3210200A (en) | 1999-01-19 | 2000-08-01 | Maxygen, Inc. | Oligonucleotide mediated nucleic acid recombination |
US7024312B1 (en) | 1999-01-19 | 2006-04-04 | Maxygen, Inc. | Methods for making character strings, polynucleotides and polypeptides having desired characteristics |
US20070065838A1 (en) * | 1999-01-19 | 2007-03-22 | Maxygen, Inc. | Oligonucleotide mediated nucleic acid recombination |
US6961664B2 (en) | 1999-01-19 | 2005-11-01 | Maxygen | Methods of populating data structures for use in evolutionary simulations |
US7384387B1 (en) | 1999-02-11 | 2008-06-10 | Maxygen, Inc. | High throughput mass spectrometry |
JP3399518B2 (en) * | 1999-03-03 | 2003-04-21 | インターナショナル・ビジネス・マシーンズ・コーポレーション | Semiconductor structure and method of manufacturing the same |
EP1165757A1 (en) | 1999-03-05 | 2002-01-02 | Maxygen, Inc. | Encryption of traits using split gene sequences |
US6531316B1 (en) | 1999-03-05 | 2003-03-11 | Maxyag, Inc. | Encryption of traits using split gene sequences and engineered genetic elements |
EP1198565A1 (en) * | 1999-07-07 | 2002-04-24 | Maxygen Aps | A method for preparing modified polypeptides |
US20040002474A1 (en) * | 1999-10-07 | 2004-01-01 | Maxygen Inc. | IFN-alpha homologues |
US7430477B2 (en) | 1999-10-12 | 2008-09-30 | Maxygen, Inc. | Methods of populating data structures for use in evolutionary simulations |
US6686515B1 (en) | 1999-11-23 | 2004-02-03 | Maxygen, Inc. | Homologous recombination in plants |
US7115712B1 (en) * | 1999-12-02 | 2006-10-03 | Maxygen, Inc. | Cytokine polypeptides |
US20040002147A1 (en) | 1999-12-29 | 2004-01-01 | Desantis Grace | Nitrilases |
CA2396320A1 (en) * | 2000-01-11 | 2001-07-19 | Maxygen, Inc. | Integrated systems and methods for diversity generation and screening |
US6998263B2 (en) | 2000-02-09 | 2006-02-14 | Genvec, Inc. | Methods of preparing and using a viral vector library |
AU2001241939A1 (en) * | 2000-02-28 | 2001-09-12 | Maxygen, Inc. | Single-stranded nucleic acid template-mediated recombination and nucleic acid fragment isolation |
EP1276861A2 (en) * | 2000-03-24 | 2003-01-22 | Maxygen, Inc. | Methods for modulating cellular and organismal phenotypes |
US7122330B2 (en) * | 2000-04-13 | 2006-10-17 | Mark Aaron Emalfarb | High-throughput screening of expressed DNA libraries in filamentous fungi |
JP2003534806A (en) * | 2000-05-31 | 2003-11-25 | ジェンベク、インコーポレイティッド | Methods and compositions for targeting adenovirus vectors |
AU2001268716A1 (en) * | 2000-06-23 | 2002-01-08 | Maxygen, Inc. | Novel chimeric promoters |
CA2411828A1 (en) | 2000-06-23 | 2002-01-03 | Maxygen, Inc. | Novel co-stimulatory molecules |
US6829753B2 (en) * | 2000-06-27 | 2004-12-07 | Fluidigm Corporation | Microfluidic design automation method and system |
WO2002004629A2 (en) * | 2000-07-07 | 2002-01-17 | Maxygen, Inc. | Molecular breeding of transposable elements |
US6858422B2 (en) * | 2000-07-13 | 2005-02-22 | Codexis, Inc. | Lipase genes |
US7435562B2 (en) | 2000-07-21 | 2008-10-14 | Modular Genetics, Inc. | Modular vector systems |
WO2002010358A2 (en) * | 2000-07-31 | 2002-02-07 | Maxygen, Inc. | Nucleotide incorporating enzymes |
AU2001280968A1 (en) * | 2000-07-31 | 2002-02-13 | Menzel, Rolf | Compositions and methods for directed gene assembly |
DE60117566T2 (en) * | 2000-08-04 | 2007-01-11 | Genencor International, Inc., Palo Alto | INCREASED PREPARATION OF 2-KETO-L-GULONIC ACID |
US6720168B2 (en) | 2000-08-04 | 2004-04-13 | Genencor International, Inc. | 2,5-DKG permeases |
WO2002016583A2 (en) * | 2000-08-24 | 2002-02-28 | Maxygen, Inc. | Constructs and their use in metabolic pathway engineering |
US20020086313A1 (en) * | 2000-09-25 | 2002-07-04 | Kilbane John J. | Application of bioinformatics for direct study of unculturable microorganisms |
MXPA02005717A (en) * | 2000-10-10 | 2003-10-14 | Diversa Corp | High throughput or capillary-based screening for a bioactivity or biomolecule. |
US7202070B2 (en) * | 2000-10-31 | 2007-04-10 | Biocatalytics, Inc. | Method for reductive amination of a ketone using a mutated enzyme |
DE10062086A1 (en) * | 2000-12-13 | 2002-07-04 | Wella Ag | Agent and method of dyeing keratin fibers |
US8008459B2 (en) * | 2001-01-25 | 2011-08-30 | Evolva Sa | Concatemers of differentially expressed multiple genes |
ATE501251T1 (en) * | 2001-01-25 | 2011-03-15 | Evolva Ltd | CELL LIBRARY |
EP1384022A4 (en) | 2001-04-06 | 2004-08-04 | California Inst Of Techn | Nucleic acid amplification utilizing microfluidic devices |
EP2322631B1 (en) | 2001-04-19 | 2014-11-12 | The Scripps Research Institute | Methods and compositions for the prodcution of orthogonal tRNA-aminoacyl-tRNA synthetase pairs |
EP2327765B1 (en) | 2001-06-21 | 2015-04-01 | BASF Enzymes LLC | Nitrilases |
US7229811B2 (en) * | 2001-08-03 | 2007-06-12 | Genencor International, Inc. | 2,5-diketo-D-gluconic acid (2,5-DKG) permeases |
JP2005508619A (en) * | 2001-08-03 | 2005-04-07 | ディヴァーサ コーポレイション | Epoxide hydrolases, nucleic acids encoding them and methods for making and using them |
US20070298474A1 (en) * | 2001-08-03 | 2007-12-27 | Manoj Kumar | Enhanced 2-Keto-L-Gulonic acid production |
GB0125043D0 (en) * | 2001-10-17 | 2001-12-12 | Biotica Tech Ltd | Production, detection and use of transformant cells |
AU2002366523A1 (en) * | 2001-12-05 | 2003-06-23 | E-Tenna Corporation | Capacitively-loaded bent-wire monopole on an artificial magnetic conductor |
DE10163748A1 (en) * | 2001-12-21 | 2003-07-17 | Henkel Kgaa | New glycosyl hydrolases |
US20050164162A1 (en) * | 2002-01-25 | 2005-07-28 | Evolva Ltd., C/O Dr. Iur. Martin Eisenring | Methods for multiple parameters screening and evolution of cells to produce small molecules with multiple functionalities |
WO2003068948A1 (en) | 2002-02-13 | 2003-08-21 | Dow Global Technologies Inc. | Over-expression of extremozyme genes in pseudomonads and closely related bacteria |
WO2003072054A2 (en) * | 2002-02-25 | 2003-09-04 | Cabot Corporation | Custom ligand design for biomolecular filtration and purification for bioseperation |
US7312085B2 (en) * | 2002-04-01 | 2007-12-25 | Fluidigm Corporation | Microfluidic particle-analysis systems |
CA2480728A1 (en) * | 2002-04-01 | 2003-10-16 | Fluidigm Corporation | Microfluidic particle-analysis systems |
JP2005523019A (en) | 2002-04-19 | 2005-08-04 | ダイヴァーサ コーポレイション | Phospholipases, nucleic acids encoding them, and methods for making and using them |
US7226771B2 (en) | 2002-04-19 | 2007-06-05 | Diversa Corporation | Phospholipases, nucleic acids encoding them and methods for making and using them |
CA2488916C (en) | 2002-06-14 | 2016-08-09 | Brian Steer | Xylanases, nucleic acids encoding them and methods for making and using them |
EP1535066A2 (en) * | 2002-06-24 | 2005-06-01 | Fluidigm Corporation | Recirculating fluidic network and methods for using the same |
EP1529110B1 (en) * | 2002-08-01 | 2011-10-05 | Evolva Ltd. | Methods of mixing large numbers of heterologous genes |
EP1576151A4 (en) | 2002-08-06 | 2006-05-17 | Verdia Inc | Ap1 amine oxidase variants |
DE60333101D1 (en) * | 2002-08-20 | 2010-08-05 | B R A I N Biotechnology Res An | IERTEN ORGANISMS |
EP1551753A2 (en) | 2002-09-25 | 2005-07-13 | California Institute Of Technology | Microfluidic large scale integration |
JP5695287B2 (en) | 2002-10-02 | 2015-04-01 | カリフォルニア インスティテュート オブ テクノロジー | Nucleic acid analysis of microfluids |
WO2004035743A2 (en) | 2002-10-16 | 2004-04-29 | The Scripps Research Institute | Site specific incorporation of keto amino acids into proteins |
US8158768B2 (en) * | 2002-12-23 | 2012-04-17 | Dynavax Technologies Corporation | Immunostimulatory sequence oligonucleotides and methods of using the same |
CN102618564B (en) | 2003-03-06 | 2014-10-29 | 维莱尼姆公司 | Amylases, nucleic acids encoding them and methods for making and using them |
CA2515583C (en) | 2003-03-07 | 2015-07-14 | Diversa Corporation | Hydrolases, nucleic acids encoding them and methods for making and using them |
DK1613733T3 (en) | 2003-04-04 | 2015-08-31 | Basf Enzymes Llc | PEKTATLYASER, nucleic acids encoding them, and methods for making and using the |
EP2535414B1 (en) | 2003-04-29 | 2017-12-13 | Pioneer Hi-Bred International Inc. | Novel glyphosate-n-acetyltransferase (gat) genes |
JP2007529993A (en) | 2003-07-02 | 2007-11-01 | シンジェンタ パーティシペーションズ アーゲー | Glucanases, nucleic acids encoding them and methods for making and using them |
WO2005012550A2 (en) * | 2003-07-31 | 2005-02-10 | Diversa Corporation | Screening methods and libraries of trace amounts of dna from uncultivated microorganisms |
CA2535526C (en) | 2003-08-11 | 2015-09-29 | Diversa Corporation | Laccases, nucleic acids encoding them and methods for making and using them |
US20060094033A1 (en) * | 2004-05-21 | 2006-05-04 | Carl Abulencia | Screening methods and libraries of trace amounts of DNA from uncultivated microorganisms |
CN103173282A (en) | 2004-06-16 | 2013-06-26 | 帝斯曼知识产权资产管理有限公司 | Compositions and methods for enzymatic decolorization of chlorophyll |
US20050282155A1 (en) * | 2004-06-17 | 2005-12-22 | Lucigen Corporation | Viral libraries from uncultivated viruses and polypeptides produced therefrom |
WO2006015374A2 (en) * | 2004-08-03 | 2006-02-09 | Novartis Vaccines And Diagnostics Inc. | Compositions and methods for preparation of nucleic acids from microbial samples |
DE102004046116A1 (en) * | 2004-09-23 | 2006-04-06 | Henkel Kgaa | Pullulanases from psychrophilic organisms |
AU2005330514B2 (en) | 2004-10-27 | 2011-05-12 | The Scripps Research Institute | Orthogonal translation components for the in vivo incorporation of unnatural amino acids |
EP1817413B1 (en) | 2004-11-11 | 2012-01-04 | Modular Genetics, Inc. | Oligonucleotide ladder assembly and system for generating molecular diversity |
WO2006099207A2 (en) | 2005-03-10 | 2006-09-21 | Diversa Corporation | Lyase enzymes, nucleic acids encoding them and methods for making and using them |
CA2861310A1 (en) | 2005-03-15 | 2006-09-28 | Bp Corporation North America Inc. | Cellulases, nucleic acids encoding them and methods for making and using them |
PT2163562E (en) | 2005-06-21 | 2013-12-19 | Xoma Us Llc | Il-1beta binding antibodies and fragments thereof |
EP2216403A3 (en) | 2006-02-02 | 2010-11-24 | Verenium Corporation | Esterases and related nucleic acids and methods |
US7776535B2 (en) * | 2006-02-06 | 2010-08-17 | Franklin And Marshall College | Site-specific incorporation of fluorinated amino acids into proteins |
CN103602692A (en) | 2006-02-10 | 2014-02-26 | 维莱尼姆公司 | Cellulolytic enzymes, nucleic acids encoding them and methods for making and using them |
TR201809912T4 (en) | 2006-02-14 | 2018-07-23 | Bp Corp North America Inc | Xylanases, nucleic acids encoding them, and methods for making and using them. |
EA019971B1 (en) | 2006-03-07 | 2014-07-30 | Верениум Корпорейшн | Aldolases, nucleic acids encoding them and methods for making and using them |
EP1994161A2 (en) | 2006-03-07 | 2008-11-26 | Cargill, Incorporated | Aldolases, nucleic acids encoding them and methods for making and using them |
CA3020590A1 (en) | 2006-08-04 | 2009-02-12 | Bp Corporation North America Inc. | Glucanases, nucleic acids encoding them and methods for making and using them |
CN113789316A (en) | 2006-09-21 | 2021-12-14 | 巴斯夫酶有限责任公司 | Phytases, nucleic acids encoding them and methods of making and using them |
AR062947A1 (en) | 2006-09-21 | 2008-12-17 | Verenium Corp | NUCLEIC ACID PHOSPHOLIPASSES CODING THEM AND METHODS TO PREPARE AND USE THEM |
WO2008073914A2 (en) | 2006-12-10 | 2008-06-19 | Dyadic International Inc. | Expression and high-throughput screening of complex expressed dna libraries in filamentous fungi |
US9862956B2 (en) | 2006-12-10 | 2018-01-09 | Danisco Us Inc. | Expression and high-throughput screening of complex expressed DNA libraries in filamentous fungi |
US8343747B2 (en) | 2006-12-21 | 2013-01-01 | Verenium Corporation | Amylases and glucoamylases, nucleic acids encoding them and methods for making and using them |
BRPI0807132A2 (en) | 2007-01-30 | 2018-12-04 | Syngenta Participations Ag | enzymes for the treatment of lignocellulosics, nucleic acids encoding them, and methods and use thereof |
EP2115153B1 (en) | 2007-03-01 | 2013-06-05 | BP Corporation North America Inc. | Nitrilases, nucleic acids encoding them and methods for making and using them |
CA2736661A1 (en) * | 2007-09-07 | 2009-03-12 | Dyadic International, Inc. | Novel fungal enzymes |
AU2008307371B2 (en) | 2007-10-03 | 2015-05-28 | Bp Corporation North America Inc. | Xylanases, nucleic acids encoding them and methods for making and using them |
US8709772B2 (en) | 2008-01-03 | 2014-04-29 | Verenium Corporation | Transferases and oxidoreductases, nucleic acids encoding them and methods for making and using them |
EP2706122A3 (en) | 2008-01-03 | 2014-06-18 | Verenium Corporation | Isomerases, nucleic acids encoding them and methods for making and using them |
US8357503B2 (en) | 2008-08-29 | 2013-01-22 | Bunge Oils, Inc. | Hydrolases, nucleic acids encoding them and methods for making and using them |
US8198062B2 (en) | 2008-08-29 | 2012-06-12 | Dsm Ip Assets B.V. | Hydrolases, nucleic acids encoding them and methods for making and using them |
US8153391B2 (en) | 2008-08-29 | 2012-04-10 | Bunge Oils, Inc. | Hydrolases, nucleic acids encoding them and methods for making and using them |
ES2660000T3 (en) | 2008-09-26 | 2018-03-20 | Ambrx, Inc. | Vaccines and microorganisms dependent on the replication of unnatural amino acids |
HUE030948T2 (en) | 2009-05-21 | 2017-06-28 | Basf Enzymes Llc | Phytases, nucleic acids encoding them and methods for making and using them |
UA111708C2 (en) | 2009-10-16 | 2016-06-10 | Бандж Ойлз, Інк. | METHOD OF OIL REFINING |
UA109884C2 (en) | 2009-10-16 | 2015-10-26 | A POLYPEPTIDE THAT HAS THE ACTIVITY OF THE PHOSPHATIDYLINOSYTOL-SPECIFIC PHOSPHOLIPASE C, NUCLEIC ACID, AND METHOD OF METHOD | |
WO2012021794A1 (en) | 2010-08-13 | 2012-02-16 | Pioneer Hi-Bred International, Inc. | Chimeric promoters and methods of use |
WO2012106579A1 (en) | 2011-02-03 | 2012-08-09 | Bristol-Myers Squibb Company | Amino acid dehydrogenase and its use in preparing amino acids from keto acids |
CN104540939A (en) | 2012-03-16 | 2015-04-22 | Bp北美公司 | Polypeptides having endoglucanase activity |
CA2872096A1 (en) | 2012-05-04 | 2013-11-07 | E. I. Du Pont De Nemours And Company | Compositions and methods comprising sequences having meganuclease activity |
EP2877576B1 (en) | 2012-07-24 | 2019-06-05 | BP Corporation North America Inc. | Xylose isomerases and their uses |
CA2904537A1 (en) | 2013-03-14 | 2014-09-25 | Pioneer Hi-Bred International, Inc. | Compositions having dicamba decarboxylase activity and methods of use |
EP2970995A1 (en) | 2013-03-14 | 2016-01-20 | Pioneer Hi-Bred International, Inc. | Compositions having dicamba decarboxylase activity and methods of use |
US10345289B2 (en) * | 2013-04-18 | 2019-07-09 | The Board Of Trustees Of The University Of Illinois | Method and apparatus for analyzing a target material |
US9580758B2 (en) | 2013-11-12 | 2017-02-28 | Luc Montagnier | System and method for the detection and treatment of infection by a microbial agent associated with HIV infection |
US11608516B2 (en) | 2015-04-15 | 2023-03-21 | Ecolab Usa Inc. | Method for determination of diversity and viability thresholds used to assess microorganisms in process samples |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4675285A (en) * | 1984-09-19 | 1987-06-23 | Genetics Institute, Inc. | Method for identification and isolation of DNA encoding a desired protein |
JPH02238882A (en) * | 1989-03-13 | 1990-09-21 | Takara Shuzo Co Ltd | Synthesis of cdna and kit therefor |
EP0528881A4 (en) * | 1990-04-24 | 1993-05-26 | Stratagene | Methods for phenotype creation from multiple gene populations |
US5352778A (en) * | 1990-04-26 | 1994-10-04 | New England Biolabs, Inc. | Recombinant thermostable DNA polymerase from archaebacteria |
US5314935A (en) | 1990-12-18 | 1994-05-24 | Elf Antar France | Bitumen/polymer component making it possible to obtain bitumen/polymer compositions with very low thermal sensitivity, capable of being employed for the production of surfacings |
US5316935A (en) * | 1992-04-06 | 1994-05-31 | California Institute Of Technology | Subtilisin variants suitable for hydrolysis and synthesis in organic media |
US6117679A (en) | 1994-02-17 | 2000-09-12 | Maxygen, Inc. | Methods for generating polynucleotides having desired characteristics by iterative selection and recombination |
US6165793A (en) | 1996-03-25 | 2000-12-26 | Maxygen, Inc. | Methods for generating polynucleotides having desired characteristics by iterative selection and recombination |
US5837458A (en) | 1994-02-17 | 1998-11-17 | Maxygen, Inc. | Methods and compositions for cellular and metabolic engineering |
US5605793A (en) | 1994-02-17 | 1997-02-25 | Affymax Technologies N.V. | Methods for in vitro recombination |
KR20040041639A (en) | 1995-04-24 | 2004-05-17 | 크로막솜 코포레이티드 | Methods for generating and screening noverl metabolic pathways |
US5654150A (en) * | 1995-06-07 | 1997-08-05 | President And Fellows Of Harvard College | Method of expression cloning |
US6096548A (en) | 1996-03-25 | 2000-08-01 | Maxygen, Inc. | Method for directing evolution of a virus |
US5783431A (en) * | 1996-04-24 | 1998-07-21 | Chromaxome Corporation | Methods for generating and screening novel metabolic pathways |
US6033883A (en) | 1996-12-18 | 2000-03-07 | Kosan Biosciences, Inc. | Production of polyketides in bacteria and yeast |
US6117659A (en) | 1997-04-30 | 2000-09-12 | Kosan Biosciences, Inc. | Recombinant narbonolide polyketide synthase |
US6090601A (en) | 1998-01-23 | 2000-07-18 | Kosan Bioscience | Sorangium polyketide synthase |
US6150513A (en) | 1998-09-16 | 2000-11-21 | Kosan Biosciences, Inc. | Polyketide synthase enzymes and recombinant DNA constructs therefor |
US6177262B1 (en) | 1998-09-22 | 2001-01-23 | Kosan Biosciences, Inc. | Recombinant host cells for the production of polyketides |
-
1996
- 1996-06-03 US US08/657,409 patent/US5958672A/en not_active Expired - Lifetime
- 1996-07-17 DK DK96925351T patent/DK0839185T3/en active
- 1996-07-17 DK DK06009151.9T patent/DK1696025T3/en active
- 1996-07-17 JP JP50682997A patent/JP2002514894A/en not_active Ceased
- 1996-07-17 CA CA2227342A patent/CA2227342C/en not_active Expired - Lifetime
- 1996-07-17 AT AT06009151T patent/ATE465246T1/en not_active IP Right Cessation
- 1996-07-17 EP EP06009151A patent/EP1696025B1/en not_active Expired - Lifetime
- 1996-07-17 ES ES96925351T patent/ES2277346T3/en not_active Expired - Lifetime
- 1996-07-17 DE DE69638168T patent/DE69638168D1/en not_active Expired - Lifetime
- 1996-07-17 EP EP96925351A patent/EP0839185B1/en not_active Expired - Lifetime
- 1996-07-17 AU AU65477/96A patent/AU6547796A/en not_active Abandoned
- 1996-07-17 AT AT96925351T patent/ATE346148T1/en not_active IP Right Cessation
- 1996-07-17 WO PCT/US1996/011854 patent/WO1997004077A1/en active IP Right Grant
- 1996-07-17 DE DE69636721T patent/DE69636721T2/en not_active Expired - Lifetime
-
1997
- 1997-12-10 US US08/988,224 patent/US6280926B1/en not_active Expired - Lifetime
-
1999
- 1999-09-28 US US09/407,525 patent/US6849395B2/en not_active Expired - Fee Related
-
2000
- 2000-11-14 US US09/713,176 patent/US6528249B1/en not_active Expired - Lifetime
-
2001
- 2001-06-06 US US09/875,412 patent/US6677115B2/en not_active Expired - Fee Related
-
2003
- 2003-02-10 US US10/364,731 patent/US20040005587A1/en not_active Abandoned
- 2003-02-25 US US10/374,576 patent/US20040029173A1/en not_active Abandoned
-
2005
- 2005-10-11 US US11/247,066 patent/US20060068493A1/en not_active Abandoned
Non-Patent Citations (1)
Title |
---|
GIBCO-BRL, Systems for Cloning. Life Technologies 1993-1994 Molecular Biology Catalogue, 1993-1994, pages 11-2 and 11-3. * |
Cited By (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6495348B1 (en) | 1993-10-07 | 2002-12-17 | Regents Of The University Of Minnesota | Mitomycin biosynthetic gene cluster |
EP0866853A4 (en) * | 1995-12-07 | 1999-09-22 | Recombinant Biocatalysis Inc | Method of screening for enzyme activity |
EP0866853A1 (en) * | 1995-12-07 | 1998-09-30 | Recombinant Biocatalysis Inc. | Method of screening for enzyme activity |
US6242211B1 (en) | 1996-04-24 | 2001-06-05 | Terragen Discovery, Inc. | Methods for generating and screening novel metabolic pathways |
US6872526B2 (en) | 1997-06-16 | 2005-03-29 | Diversa Corporation | High throughput screening for novel Bioactivities |
EP1009858A1 (en) * | 1997-06-16 | 2000-06-21 | Diversa Corporation | High throughput screening for novel enzymes |
EP1009858A4 (en) * | 1997-06-16 | 2001-03-07 | Diversa Corp | High throughput screening for novel enzymes |
US6806048B2 (en) | 1997-06-16 | 2004-10-19 | Diversa Corporation | Method for high throughput screening of an environmental library |
US6602675B2 (en) | 1997-06-16 | 2003-08-05 | Diversa Corporation | High throughput screening of mycelia for bioactivities or biomolecules |
EP1025262A1 (en) * | 1997-08-26 | 2000-08-09 | Diversa Corporation | Screening for novel bioactivities |
EP1025262A4 (en) * | 1997-08-26 | 2005-10-12 | Diversa Corp | Screening for novel bioactivities |
WO1999015897A1 (en) * | 1997-09-19 | 1999-04-01 | Chiron Corporation | Subtractive protein screening for gene identification |
US6846627B2 (en) * | 1997-10-15 | 2005-01-25 | Diversa Corporation | Screening for novel compounds which regulate biological interactions |
US6261842B1 (en) | 1997-10-23 | 2001-07-17 | Wisconsin Alumni Research Foundation | Microorganism genomics, compositions and methods related thereto |
US7008767B2 (en) | 1997-10-23 | 2006-03-07 | Wisconsin Alumni Research Foundation | Microorganism genomics, compositions and methods related thereto |
WO2001081567A3 (en) * | 2000-04-26 | 2002-03-21 | Wisconsin Alumni Res Found | Method for producing genomic libraries and genomic libraries produced therewith |
WO2001081567A2 (en) * | 2000-04-26 | 2001-11-01 | Wisconsin Alumni Research Foundation | Method for producing genomic libraries and genomic libraries produced therewith |
WO2007136833A2 (en) * | 2006-05-19 | 2007-11-29 | Codon Devices, Inc. | Methods and compositions for aptamer production and uses thereof |
WO2007136833A3 (en) * | 2006-05-19 | 2008-01-24 | Codon Devices Inc | Methods and compositions for aptamer production and uses thereof |
Also Published As
Publication number | Publication date |
---|---|
EP1696025A3 (en) | 2006-09-13 |
DE69638168D1 (en) | 2010-06-02 |
US20060068493A1 (en) | 2006-03-30 |
US5958672A (en) | 1999-09-28 |
US6677115B2 (en) | 2004-01-13 |
ES2277346T3 (en) | 2007-07-01 |
US20040005587A1 (en) | 2004-01-08 |
CA2227342C (en) | 2011-03-29 |
DK1696025T3 (en) | 2010-07-19 |
ATE465246T1 (en) | 2010-05-15 |
ATE346148T1 (en) | 2006-12-15 |
EP0839185A4 (en) | 2002-10-30 |
US20020172944A1 (en) | 2002-11-21 |
DK0839185T3 (en) | 2007-02-19 |
US20040029173A1 (en) | 2004-02-12 |
DE69636721D1 (en) | 2007-01-04 |
US20020086279A1 (en) | 2002-07-04 |
EP0839185A1 (en) | 1998-05-06 |
US6280926B1 (en) | 2001-08-28 |
AU6547796A (en) | 1997-02-18 |
CA2227342A1 (en) | 1997-02-06 |
DE69636721T2 (en) | 2008-01-24 |
US6849395B2 (en) | 2005-02-01 |
EP1696025B1 (en) | 2010-04-21 |
EP1696025A2 (en) | 2006-08-30 |
US6528249B1 (en) | 2003-03-04 |
JP2002514894A (en) | 2002-05-21 |
EP0839185B1 (en) | 2006-11-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0839185B1 (en) | Screening methods for enzymes and enzyme kits | |
US6168919B1 (en) | Screening methods for enzymes and enzyme kits | |
US6054267A (en) | Method for screening for enzyme activity | |
US6344328B1 (en) | Method for screening for enzyme activity | |
US6030779A (en) | Screening for novel bioactivities | |
US6632600B1 (en) | Altered thermostability of enzymes | |
US20030211543A1 (en) | Enzyme kits and libraries | |
AU720334B2 (en) | Method of screening for enzyme activity | |
US6368798B1 (en) | Screening for novel bioactivities | |
US6790605B1 (en) | Methods for obtaining a desired bioactivity or biomolecule using DNA libraries from an environmental source | |
AU767618B2 (en) | Screening methods for enzymes and enzyme kits | |
AU756201B2 (en) | Method of screening for enzyme activity | |
AU2007202329A1 (en) | Method of screening for enzyme activity | |
AU2003200812A2 (en) | Method of screening for enzyme activity | |
US20020164580A1 (en) | Combinatorial screening of mixed populations of organisms |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU CA IL JP US US US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
ENP | Entry into the national phase |
Ref document number: 2227342 Country of ref document: CA Ref country code: CA Ref document number: 2227342 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1996925351 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1996925351 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 08983367 Country of ref document: US |
|
WWG | Wipo information: grant in national office |
Ref document number: 1996925351 Country of ref document: EP |